gnt

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug NelonemdazGNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the…

4 months ago
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug NelonemdazGNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the…

4 months ago